WASHINGTON (Xinhua): Hospitalised patients with advanced Covid-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a release from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) on Wednesday (April 29).
The conclusion came out of preliminary data analysis from a randomised, controlled trial involving 1,063 patients, which began on Feb. 21.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
